Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: A randomized, controlled trial

Annals of Internal Medicine

Volumn 152, Issue 12, 2010, Pages 761-769

  Palmer, Scott M ^a   Limaye, Ajit P ^b   Banks, Missy ^c   Gallup, Dianne ^c   Chapman, Jeffrey ^d   Lawrence, E Clinton ^e   Dunitz, Jordan ^f   Milstone, Aaron ^g   Reynolds, John ^h   Yung, Gordon L ⁱ   Chan, Kevin M ^j   Aris, Robert ^k   Garrity, Edward ^l   Valentine, Vincent ^m   McCall, Jonathan ^c   Chow, Shein Chung ^a   Davis, Robert Duane ^a   Avery, Robin ^d  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e EMORY UNIVERSITY HOSPITAL   (United States)

^f Department of Medicine   (United States)

^g VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^h Div Pulmon and Critical Care Med   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF MICHIGAN   (United States)

^k UNIVERSITY OF NORTH CAROLINA   (United States)

^l UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^m UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VALGANCICLOVIR; VIRUS DNA; ANTIVIRUS AGENT; DRUG DERIVATIVE; GANCICLOVIR;

ABNORMAL LABORATORY RESULT; ACUTE GRAFT REJECTION; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ANTIVIRAL RESISTANCE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FOLLOW UP; GRAFT RECIPIENT; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HUMAN; LEUKOCYTE COUNT; LIVER FUNCTION TEST; LONG TERM CARE; LUNG GRAFT REJECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPHIL COUNT; OPPORTUNISTIC INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SIDE EFFECT; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS MUTATION; DRUG ADMINISTRATION; FEMALE; IMMUNOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PROSPECTIVE STUDY; VIREMIA; VIRUS PNEUMONIA;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GANCICLOVIR; HUMANS; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PNEUMONIA, VIRAL; PROSPECTIVE STUDIES; VIREMIA;

EID: 77954070106     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-152-12-201006150-00003     Document Type: Article

References (32)

1. Christie JD, Edwards LB, Aurora P, Dobbels F, Kirk R, Rahmel AO, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fifth official adult lung and heart/lung transplantation report - 2008. J Heart Lung Transplant. 2008;27:957-69. [PMID: 18765187]
2. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med. 1998;338:1741-51. [PMID: 9624195]
3. Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation. JAMA. 1989;261:3607-9. [PMID: 2542634]
4. Humar A, Kumar D, Preiksaitis J, Boivin G, Siegal D, Fenton J, et al. A trial of valganciclovir prophylaxis for cytomegalovirus prevention in lung transplant recipients. Am J Transplant. 2005;5:1462-8. [PMID: 15888055]
5. Perreas KG, McNeil K, Charman S, Sharples LD, Wreghitt T, Wallwork J. Extended ganciclovir prophylaxis in lung transplantation. J Heart Lung Transplant. 2005;24:583-7. [PMID: 15896756]
6. Hertz MI, Jordan C, Savik SK, Fox JM, Park S, Bolman RM 3rd, et al. Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation. J Heart Lung Transplant. 1998;17:913-20. [PMID: 9773865] (Pubitemid 28440855)
7. Roche Pharmaceuticals. Valcyte (valganciclovir hydrochloride tablets) prescribing information. Accessed at www.fda.gov/medwaTCH/SAFETY/2003/valcyte- pi.pdf on 20 November 2008.
8. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B, et al; Valganciclovir Solid Organ Transplant Study Group. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant. 2004;4:611-20. [PMID: 15023154]
9. Valentine VG, Weill D, Gupta MR, Raper B, Laplace SG, Lombard GA, et al. Ganciclovir for cytomegalovirus: a call for indefinite prophylaxis in lung transplantation. J Heart Lung Transplant. 2008;27:875-81. [PMID: 18656801]
10. Palmer SM, Grinnan DC, Diane Reams B, Steele MP, Messier RH, Duane Davis R. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir. Clin Transplant. 2004;18:179-85. [PMID: 15016133]
11. Zamora MR, Nicolls MR, Hodges TN, Marquesen J, Astor T, Grazia T, et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant. 2004;4:1635-42. [PMID: 15367218]
12. Jaksch P, Zweytick B, Kerschner H, Hoda AM, Keplinger M, Lang G, et al. Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy. J Heart Lung Transplant. 2009;28:670-5. [PMID: 19560694]
13. U.S. Food and Drug Administration. Guidance for industry: E6 Good Clinical Practice: Consolidated guidance (1996). Accessed at www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ ucm073122.pdf on 15 March 2010.
14. Boeckh M, Huang M, Ferrenberg J, Stevens-Ayers T, Stensland L, Nichols WG, et al. Optimization of quantitative detection of cytomegalovirus DNA in plasma by real-time PCR. J Clin Microbiol. 2004;42:1142-8. [PMID: 15004066]
15. Castor J, Cook L, Corey L, Jerome KR. Rapid detection directly from patient serum samples of human cytomegalovirus UL97 mutations conferring ganciclovir resistance. J Clin Microbiol. 2007;45:2681-3. [PMID: 17537934]
16. Chou S. Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. Rev Med Virol. 2008;18:233-46. [PMID: 18383425]
17. Stewart S, Fishbein MC, Snell GI, Berry GJ, Boehler A, Burke MM, et al. Revision of the 1996 working formulation for the standardization of nomenclature in the diagnosis of lung rejection. J Heart Lung Transplant. 2007;26:1229-42. [PMID: 18096473]
18. Chow SC, Lu Q, Tse SK. Statistical analysis for two-stage seamless design with different study endpoints. J Biopharm Stat. 2007;17:1163-76. [PMID: 18027223]
19. Kruger RM, Paranjothi S, Storch GA, Lynch JP, Trulock EP. Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients. J Heart Lung Transplant. 2003;22:754-63. [PMID: 12873543] (Pubitemid 36842927)
20. Drew WL. Ganciclovir resistance: a matter of time and titre. Lancet. 2000;356:609-10. [PMID: 10968428]
21. Limaye AP, Corey L, Koelle DM, Davis CL, Boeckh M. Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants. Lancet. 2000;356:645-9. [PMID: 10968438]
22. Razonable RR, van Cruijsen H, Brown RA, Wilson JA, Harmsen WS, Wiesner RH, et al. Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. J Infect Dis. 2003;187:1801-8. [PMID: 12751039]
23. Drew WL, Paya CV, Emery V. Cytomegalovirus (CMV) resistance to antivirals. Am J Transplant. 2001;1:307-12. [PMID: 12099372]
24. Gilbert C, Handfield J, Toma E, Lalonde R, Bergeron MG, Boivin G. Emergence and prevalence of cytomegalovirus UL97 mutations associated with ganciclovir resistance in AIDS patients. AIDS. 1998;12:125-9. [PMID: 9468360]
25. Boivin G, Goyette N, Gilbert C, Roberts N, Macey K, Paya C, et al. Absence of cytomegalovirus-resistance mutations after valganciclovir prophylaxis, in a prospective multicenter study of solid-organ transplant recipients. J Infect Dis. 2004;189:1615-8. [PMID: 15116297]
26. Cainelli F, Vento S. Infections and solid organ transplant rejection: a cause-and-effect relationship? Lancet Infect Dis. 2002;2:539-49. [PMID: 12206970]
27. Sharples LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant. 2002;21:271-81. [PMID: 11834356]
28. Chmiel C, Speich R, Hofer M, Michel D, Mertens T, Weder W, et al. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis. 2008;46:831-9. [PMID: 18269330]
29. Weigt SS, Elashoff RM, Keane MP, Strieter RM, Gomperts BN, Xue YY, et al. Altered levels of CC chemokines during pulmonary CMV predict BOS and mortality post-lung transplantation. Am J Transplant. 2008;8:1512-22. [PMID: 18513272]
30. Singh N. Late-onset cytomegalovirus disease as a significant complication in solid organ transplant recipients receiving antiviral prophylaxis: a call to heed the mounting evidence. Clin Infect Dis. 2005;40:704-8. [PMID: 15714416] (Pubitemid 40381344)
31. Humar A, Lebranchu Y, Vincenti F, Punch J, Abramowicz D, et al. The IMPACT Study: valganciclovir prophylaxis for until 200 days post-transplant in high risk kidney recipients substantially reduces the incidence of CMV disease [Abstract]. Presented at American Transplant Congress, 1 June 2009, Boston, MA. Abstract #201. Accessed at www.atcmeeting.org/2009/pdfs/ATC-09-Days.pdf on 29 April 2010.
32. Westall GP, Mifsud NA, Kotsimbos T. Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity. Am J Transplant. 2008;8:1749-54. [PMID: 18557732]